100981-43-9 Usage
Description
Ebrotidine, also known as Ebrocit, is a histamine H2-receptor antagonist that has demonstrated gastroprotective properties against gastric mucosal damage. It was launched in Spain as a gastroprotective agent and is prepared from 4-bromobenzenesulfonamide in two steps. Ebrotidine's activity stems from its ability to antagonize histamine H2-receptors, showing a higher affinity than other H2-receptor antagonists like Ranitidine and cimetidine. This results in increased antisecretory potency and gastroprotection through various mechanisms, including increased gastric mucus production, enhanced physiochemical properties, and increased mucin glycosylation and sulfation. It also acts on gastric mucosal EGF and PDGF receptor expression and is involved in nitric oxide production, leading to enhanced mucosal blood flow and anti H. pylori activity. Additionally, Ebrotidine has diminished P450 binding, which eliminates the possibility of mutagenic nitrosoamine formation.
Uses
Used in Pharmaceutical Industry:
Ebrotidine is used as a gastroprotective agent for treating gastric mucosal damage. It provides gastroprotection through increased gastric mucus production, enhanced physiochemical properties (decreased permeability of H+), and an increase in mucin glycosylation and sulfation. It also acts on gastric mucosal EGF and PDGF receptor expression and is involved in nitric oxide production, leading to enhanced mucosal blood flow and anti H. pylori activity.
Used in Gastrointestinal Treatment:
Ebrotidine is used as a histamine H2-receptor antagonist for treating conditions related to excess gastric acid production, such as peptic ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. Its higher affinity for H2-receptors compared to other antagonists results in greater antisecretory potency, making it an effective treatment option for these conditions.
Used in Research and Development:
Ebrotidine can be used in research and development for studying the mechanisms of gastric mucosal protection and the role of histamine H2-receptors in gastrointestinal health. Its unique properties and higher affinity for H2-receptors make it a valuable tool for understanding the underlying processes and developing new therapeutic strategies for gastrointestinal disorders.
Originator
Ferrer (Spain)
references
[1]. patel s s, wilde m i. ebrotidine. drugs, 1996, 51(6): 974-80; discussion 981.[2]. romero a, gómez f, villamayor f, et al. study of the population of enterochromaffin-like cells in mouse gastric mucosa after long-term treatment with ebrotidine. toxicologic pathology, 1996, 24(2): 160-165.
Check Digit Verification of cas no
The CAS Registry Mumber 100981-43-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,0,9,8 and 1 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 100981-43:
(8*1)+(7*0)+(6*0)+(5*9)+(4*8)+(3*1)+(2*4)+(1*3)=99
99 % 10 = 9
So 100981-43-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21)
100981-43-9Relevant articles and documents
Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine
Rozman,Galceran,Anglada,Albet
, p. 252 - 254 (1994)
Ebrotidine is a new H2-receptor antagonist which exhibits a remarkable ability for gastric mucosal protection. A preliminary metabolic pathway for this compound was proposed and the hypothetic metabolites were synthesized. The presence of ebrot
Synthesis and assessment of formamidines as new histamine H2-receptor antagonists
Anglada, Lluis,Raga, Manuel,Marquez, Miguel,Sacristan, Aurelio,Castello, Josep M.,Ortiz, Jose A.
, p. 431 - 434 (2007/10/03)
Four series of compounds whose substructure contains a formamidine functionalized as a novel group in the chemistry of histamine H2-receptors have been synthesized. Series design, synthesis and pharmacological data including inhibition of histamine-stimulated acid secretion, inhibition of acid secretion p.o. and pA2 are reported. N-[(E)-[[2- [[[2[(Diaminomethylene)amino]-4- thiazolyl]methyl]thio]ethyl]amino]methylene]-4-bromo-benzenesu llfonamide (ebrotidine, CAS 100981-43-9, FI-3542) was selected for further research.
SULFONAMIDINES, PROCESS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
-
, (2008/06/13)
Sulfonamidine is disclosed of the general formula (I): EQU1 wherein R is a group selected from 2-(5-methyl-1H-imidazole-4-yl) methyl!thio!ethyl!, 2-5-(dimethylamino)methyl!-2-furanyl!methyl!thio!ethyl, 2-2-(aminoiminomethyl)amino!-4-thiazolyl!methyl!thio!ethyl! or 3-3-(1-piperidinylmethyl)phenoxy! propyl and R 1 is alkyl; or a phenyl group optionally substituted by alkyl, halogen, nitro, alkoxy, alkanoylamino, carboxylic acid, alkoxycarbonyl, dialkylamino, alkylsulphonyl, alkylsulphonylamino or alkylthio; or 1,3,4-thiadiazole-2-yl substituted by alkanoylamino, and the pharmaceutically acceptable salts thereof, as well as a process for preparing these compounds and pharmaceutical compositions containing the same. These compounds have antiulcer activity and can be used in the treatment of peptic ulcers and other pathologies caused or stimulated by gastric acidity.